Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

Stock Information for OSE Immunotherapeutics

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OSE Immunotherapeutics

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote "FOR" the Proposed Merger with Coherus BioSciences
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF
Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BG, SURF, KLR
ALERT: The M&A Class Action Firm Continues Investigating the Merger - HT, ABCM, THRN, SURF
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HEP, SCU, SURF
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.